|Bid||2.9100 x 800|
|Ask||2.9600 x 1400|
|Day's Range||2.9110 - 3.0000|
|52 Week Range||1.6000 - 4.0400|
|Beta (3Y Monthly)||2.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MaxHealth to distribute Biomerica’s colorectal screening test to help identify the early warning signs of colorectal cancer. IRVINE, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (BMRA) announced it has signed an exclusive sales and distribution agreement with MaxHealth for the sale of its EZ Detect product in China. The agreement requires MaxHealth to meet annual minimum purchase requirements, which in aggregate, equal $17 million over the initial seven year term and further requires an upfront pre-payment of $1 million after meeting certain conditions.
Biomerica, Inc. (BMRA) today reported net sales of $4,034,822 for the nine months ending February 28, 2019, compared to $4,433,785 for the period ended February 28, 2018. Sales for the three months ending February 28, 2019 were $1,261,161 compared to $1,375,666 for the period ended February 28, 2018. In addition, the Company announced progress in both its InFoods® IBS clinical study and H. pylori study as well as the issuance of its first patent pertaining to the Company’s InFoods® family of products that are designed to allow for a revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. “We are very pleased that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products. The patent validates the unique InFoods product which is designed to allow physicians to offer new and better therapies to patients.
Biomerica, Inc. (BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products that allow for revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application (#15/526,240) contains numerous claims that broadly cover a product that enables physicians to identify patient specific foods (e.g.
LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...
Based on recent discussions between Biomerica and the United States Food and Drug Administration (FDA) regarding the regulatory pathway for final FDA clearance of the Company’s H. pylori product, the Company needs less than 40 clinical trial patient samples in addition to the 210 samples already collected. These final clinical patient samples are expected to be collected over the next few months, after which the Company will complete the remaining analytical and clinical agreement studies and prepare a submission to the FDA for 510(k) FDA clearance. Helicobacter pylori (H. pylori) infection is one of the most common, chronic, bacterial infections affecting humans. Complications associated with H. pylori infections include ulcers, inflammation of the stomach lining and stomach cancer. The diagnosis of H. pylori is important given that specific antibiotic treatment is highly effective in improving outcomes.
Biomerica, Inc. (BMRA) today reported net sales of $1,500,791 for the three months ended November 30, 2018, compared to $1,613,636 for the same period in the previous year. Net sales were $2,773,661 for the six months ended November 30, 2018 compared to $3,058,119 for the same period in last year. The Company ended the quarter with approximately $798,000 in backlog for open orders, which were not shipped as of November 30, 2018. Biomerica announced a net loss for the three months ended November 30, 2018 of $477,244, or $0.05 per share, versus a net loss of $268,661, or $0.03 per share, in the previous fiscal year during the same quarter. The net loss for the six months ended November 30, 2018 was $928,984, or $0.10 per share, compared to net loss of $475,720, or $0.06 per share in the prior fiscal year.
Biomerica, Inc. (BMRA) announced that is has signed a three year agreement with Medline Industries for the distribution of Biomerica’s EZ Detect™ colorectal disease screening test designed to help identify an early warning sign of colorectal cancer. The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. With over 18,000 employees worldwide, 1,600 direct sales reps and $10.2 billion in sales, Medline Industries is ranked 32 on the Forbes list of largest private companies. Medline is the largest privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care (from large healthcare systems and independent physician practices to home health patients and their families).
NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p